This is a reference monoclonal antibody (ongericimab) targeting PCSK9, a protein that regulates LDL cholesterol levels. It serves as a standard for research, assay development, quality control, and bioanalytical testing in the development of PCSK9 inhibitors for treating hypercholesterolemia and lipid disorders. By mimicking the binding and inhibitory mechanism of therapeutic anti-PCSK9 antibodies, it helps evaluate potency, specificity, and efficacy in preclinical and analytical settings.